| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/22/2006 | CA2604463A1 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents |
| 06/22/2006 | CA2591715A1 Agent for regulating bone formation |
| 06/22/2006 | CA2591413A1 Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases |
| 06/22/2006 | CA2591123A1 Farnesyl protein transferase inhibitors and methods for treating proliferative diseases |
| 06/22/2006 | CA2590979A1 Novel farnesyl protein transferase inhibitors and their use to treat cancer |
| 06/22/2006 | CA2590881A1 Silicon compounds and their use |
| 06/22/2006 | CA2590877A1 Silicon compounds and their use |
| 06/22/2006 | CA2590845A1 Novel hydantoin derivatives as metalloproteinase inhibitors |
| 06/22/2006 | CA2590843A1 Novel hydantoin derivatives as metalloproteinase inhibitors |
| 06/22/2006 | CA2590768A1 Rnai modulation of mll-af4 and uses thereof |
| 06/22/2006 | CA2590479A1 Triazole substituted aminobenzophenone compounds |
| 06/22/2006 | CA2590431A1 Novel pharmaceutical composition containing at least one dolastatin 10 derivative |
| 06/22/2006 | CA2590303A1 Cytotoxic antibody directed against type b lymphoid hematopoietic proliferations |
| 06/22/2006 | CA2590294A1 Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| 06/22/2006 | CA2589992A1 Treatment of solid cancers |
| 06/22/2006 | CA2589793A1 4-(4-(imidazol-4-yl)pyrimidin-2-ylamino) benzamides as cdk inhibitors |
| 06/22/2006 | CA2589521A1 Combinations of 7-t-butoxyiminomethylcamptothecin with one or more chemotherapeutic agents for treating cancers |
| 06/22/2006 | CA2589501A1 Indolinones and their use as antiproliferative agents |
| 06/22/2006 | CA2589363A1 Spiro derivatives as lipoxygenase inhibitors |
| 06/22/2006 | CA2588389A1 Substituted phenols as active agents inhibiting vegf production |
| 06/22/2006 | CA2588384A1 Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control |
| 06/22/2006 | CA2587589A1 Engineered antibodies and immunoconjugates |
| 06/22/2006 | CA2587285A1 Actinomadura chromoprotein, apoprotein, and gene cluster |
| 06/22/2006 | CA2529630A1 New derivatives of benzo[b]pyrano[3,2-h] acridin-7-one cinnamates, their preparation process and the pharmaceutical compositions that contain them |
| 06/21/2006 | EP1672065A1 Protein expressed in nk cell |
| 06/21/2006 | EP1671965A2 Oxacarbocyclic oligomers of fumaric acid |
| 06/21/2006 | EP1671957A1 Thiadiazoline derivatives |
| 06/21/2006 | EP1671949A2 Substituted phenylamines and pyridinylamines |
| 06/21/2006 | EP1671943A1 Preparation of EKB-569 and related intermediates |
| 06/21/2006 | EP1671654A2 Conjugates of hydroxyalkyl starch and an active agent |
| 06/21/2006 | EP1671647A1 Medicament for treating cancer |
| 06/21/2006 | EP1671645A1 Remedy and detection drug for bile duct cancer |
| 06/21/2006 | EP1671632A1 Pharmaceutical combination of angiotensin II antagonists and ACE inhibitors |
| 06/21/2006 | EP1671631A2 Compositions for the treatment of chronic lymphocytic leukemia |
| 06/21/2006 | EP1671629A1 Human beta-defensin secretion promoter |
| 06/21/2006 | EP1671625A1 Nanoparticles |
| 06/21/2006 | EP1670825A2 Antibodies to m-csf |
| 06/21/2006 | EP1670802A2 Novel heterocyclic compounds as hsp90-inhibitors |
| 06/21/2006 | EP1670800A1 Ceratamines a and b, and analogues, syntheses and pharmaceutical compositions thereof |
| 06/21/2006 | EP1670791A2 Thiophene-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| 06/21/2006 | EP1670786A1 Quinazoline derivatives |
| 06/21/2006 | EP1670785A1 Salts and polymorphs of a pyrrole-substituted indolinone compound |
| 06/21/2006 | EP1670782A1 Quinazoline derivatives |
| 06/21/2006 | EP1670781A1 Quinoline derivatives and quinazoline derivatives, medicaments containing said compounds, use thereof, and method for the production thereof |
| 06/21/2006 | EP1670780A2 Compounds and compositions as protein kinase inhibitors |
| 06/21/2006 | EP1670771A1 Compounds and compositions as protein kinase inhibitors |
| 06/21/2006 | EP1670514A2 Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor |
| 06/21/2006 | EP1670513A2 Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy |
| 06/21/2006 | EP1670510A1 Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis. |
| 06/21/2006 | EP1670494A1 Glatiramer acetate for use as an immuno-modulatory agent |
| 06/21/2006 | EP1670491A2 Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
| 06/21/2006 | EP1670487A1 Therapeutic formulations |
| 06/21/2006 | EP1670469A1 Use of known active ingredients as radical scavengers |
| 06/21/2006 | EP1670455A2 Treatment of diseases involving erbb2 kinase overexpression |
| 06/21/2006 | EP1670416A2 Methods for treating igf1r-inhibitor induced hyperglycemia |
| 06/21/2006 | EP1463504B1 Compositions comprising epothilones and their use for the treatment of the carcinoid syndrome |
| 06/21/2006 | EP1450781B1 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| 06/21/2006 | EP1366049B1 Pirazino¬1'2':1,6|pyrido¬3,4-b|indole derivatives |
| 06/21/2006 | EP1305041B1 Medicament for the immunotherapy of malignant tumours |
| 06/21/2006 | EP1284952B1 Substituted chalcones as therapeutic compounds |
| 06/21/2006 | EP1267866B1 The treatment of respiratory diseases |
| 06/21/2006 | EP1263440B1 Cephalotaxine alkaloid combination compositions and uses thereof |
| 06/21/2006 | EP1251850B1 Use of a combination preparation in cancer therapy |
| 06/21/2006 | EP1244647B1 Quinazoline derivatives as vegf inhibitors |
| 06/21/2006 | EP1227810B1 Treating cancer by increasing intracellular malonyl coa levels |
| 06/21/2006 | EP1208092B1 Sulfonamide derivative as a matrix metalloproteinase inhibitor |
| 06/21/2006 | EP1192185B1 Apo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM |
| 06/21/2006 | EP1189931B1 Peptide compounds that bind her2 |
| 06/21/2006 | EP1173163B1 Pharmaceutical compositions of tetrac and methods of use thereof |
| 06/21/2006 | EP1140170B1 Antibody fragments for the topical treatment of ocular diseases |
| 06/21/2006 | EP0971601B1 Decaffeinated mate extracts and the use thereof |
| 06/21/2006 | EP0932626B1 G protein-coupled receptor antagonists |
| 06/21/2006 | EP0912198B1 Immunoliposomes that optimize internalization into target cells |
| 06/21/2006 | EP0815100B1 Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| 06/21/2006 | CN1791594A 2-aminoquinoline derivative |
| 06/21/2006 | CN1791568A Hsp90 family protein inhibitors |
| 06/21/2006 | CN1791421A Method for inducing mammary epithelial cell differentiation |
| 06/21/2006 | CN1791414A Use of steroid derivatives for the treatment of angiotensin ii related disease e.g. cardiovascular and proliferative disorders |
| 06/21/2006 | CN1791403A Compositions and methods for treating cancer |
| 06/21/2006 | CN1791396A Combination of histone deacetylase inhibitors with chemotherapeutic agents |
| 06/21/2006 | CN1789424A Dual target effected chimera recombinant, its construction method and application |
| 06/21/2006 | CN1789277A Diisopropoxy phosphoryl dipeptide trimethoxy benzamide compound and its preparation process |
| 06/21/2006 | CN1789264A Crystals including a malic acid salt of a 3-pyrrole substituted 2-indolinone, and compositions thereof |
| 06/21/2006 | CN1788760A Cancer-treating capsule and its preparation process |
| 06/21/2006 | CN1788723A Liposome microsphere injection liquid containing demethylate disodium cantharidinate and its preparation method |
| 06/21/2006 | CN1788719A Leucogen slow release composition and preparation process thereof |
| 06/21/2006 | CN1788588A Preparation method of anti-tumour mutation milk containing micro ash tree pollen, pine pollen, lucid ganoderma powder etc. |
| 06/21/2006 | CN1788587A Preparation method of anti-tumour mutation soybean milk containing micro ash tree pollen, pine pollen, lucid ganoderma powder etc. |
| 06/21/2006 | CN1788586A Preparation method of anti-tumour mutation milk powder containing micro ash tree pollen, pine pollen, lucid ganoderma powder etc. |
| 06/21/2006 | CN1788585A Preparation method of anti-tumour mutation soybean milk powder containing micro ash tree pollen, pine pollen, lucid ganoderma powder etc. |
| 06/21/2006 | CN1788579A Preparation method of anti-tumour mutation sour soybean milk containing micro ash tree pollen, pine pollen, lucid ganoderma powder etc. |
| 06/21/2006 | CN1260367C Fortified fusion protein possessing angiopoiesis-inhibiting and anti-tumour actions |
| 06/21/2006 | CN1260360C Lipid kinase |
| 06/21/2006 | CN1260359C High-solublity expressed tricholsanthin mutant and its preparing method |
| 06/21/2006 | CN1260240C 5'-deoxycytidine derivatives |
| 06/21/2006 | CN1260239C Fructose spiro-compound with anti-cancer activity |
| 06/21/2006 | CN1260227C 5-membered ring heterocyclic compounds with nitrogen |
| 06/21/2006 | CN1260221C Method for preparing platinum(II) metal complex eptaplatin |
| 06/21/2006 | CN1260215C Antagon of endostadin receptor pyrazole carboxylic acids |
| 06/21/2006 | CN1259966C Chinese medicine for treating leukemia |